At first glance there are no financials and there is a thought that the first deal would be modest. So why is the whole bigger than the sum of the parts? Here are some reasons;
validation of the science and confirmation of the utility of the platform; a rising tide raises all boats including expectations around the AD-214 program. GE Healthcare, one of the world's largest healthcare companies, is a huge rising tide. The agreement will be at the back end of a great deal of due diligence which tends to instil confidence that AdAlta is a serious player on the global biotech stage in next generation antibodies.
the resignation of the CEO can be seen within context; rather than portending the beginning of the end its now looking like the next stage in the transition from discovery to development and commercialisation. If GE Healthcare feel comfortable with the management of AdAlta then that's arguably good enough reassurance for investors.
the agreement would appear to be open ended; initial work will involve developing an i-body for Granzyme B but it would appear that success would lead to development of other i-bodies for diagnostic testing.
1AD Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)